LivaNova Q3 revenue $357.8M (+12.5% organic); raises FY2025 EPS guidance to $3.80-$3.90

LivaNova PLC

2025-Q3 EPS reported -$5.01 revenue$1,027,132,000

Third-quarter revenue $357.8M, up 12.5% reported, 11% constant-currency, and 12.5% organic vs prior year.
GAAP diluted EPS $0.49; adjusted diluted EPS $1.11.
Raised FY2025 guidance: revenue growth 8.5%-9.5% constant currency, EPS $3.80-$3.90, FCF $160M-$180M.
Initiated commercial launch of Essenz Perfusion System in China, the second-largest heart-lung machine market.
Appointed Donald Zurbay to the Board of Directors and Audit and Compliance Committee.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.